A confusion of drug packaging appears to be responsible for the deaths of three infants.
FDA and pharmaceutical company warns of drug mix-up
The FDA and Baxter International Inc. (a pharmaceutical company) are warning health care providers about mix-ups of two heparin products. These mix-ups recently resulted in the death of three infants. The deaths occurred when a higher dose of Heparin Sodium Injection, at 10,000 units a milliliter, was inadvertently administered instead of a lower dose. Both products are in the same size vial and use different shades of blue as the prominent background color on their label. The similarity between the two bottles makes providers prone to medical malpractice in administering the drug.
Thank you, Levin & Perconti, for the alert.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.